Mechanism Of Erzhi Tiangui Decoction In Treating Kidney Yin-deficiency Hypogonadotropic Hypogonadism

Objective: To evaluate the mechanism of Erzhi Tiangui Granule in treating kidney yin-deficiency hypogonadotropic hypogonadism.Method: 60 cases of kidney yin-deficiency hypogonadotropic hypogonadism patients were randomly divided into two groups, the study group were treated with erzhi tiangui granule, the control group were treated with liuwei dihuang granule, and choose 30 cases of outpatient women of childbearing age in the same period as blank.Three groups of patients were detected sex hormones and uterine length, thickness of endometrium, ovary average volume, the number of follicles sinus, hemodynamic changes in the uterus and ovaries in the 2-3 days of menstrual period.Study and control groups were measured uterine and ovarian artery hemodynamics, serum LH, E2, P, VEGF levels and endometrial thickness, type, endometrial blood flow distribution on the HCG-injected day.Study and control group are compared menstrual changes, changes in sex hormone levels and kidney-deficiency before and after treatment.Results: 1. Uterine and ovarian blood flow of the study group compared with the control group was high speed and low resistance on the HCG- injected day.E2?LH and VEGF levels of the study group were higher than those in the control group.The endometrial thickness, type and vascular morphology of the study group were better than those in the control group.The difference between the two groups was statistically significant. 2. After treatment, the levels of FSH, LH and E2 were increased, the amount of menstruation and the period of the menstrual cycle were improved, and the improvement of kidney deficiency syndrome was more obvious than that in the control group, and the difference between the two groups was statistically significant. 3. The rates of ovulation and pregnancy in the study group were higher than those in the control group, the difference was statistically significant.Conclusion: Erzhi tiangui granule can improve HH patients FSH, LH, E2 levels during the follicular phase, increase VEGF levels around ovulation, improve preovulatory LH levels, improve endometrial receptivity, promoting follicular growth, maturation and discharge, and further improve embryo implantation rate and pregnancy rate.